BGTF 027
Alternative Names: AAV.7m8-L-opsin; AAV.7m8GMTNCGLOpsin; AAV2.7m8-MNTC-hOPN1LW; ADVM-062Latest Information Update: 31 Jul 2025
At a glance
- Originator Adverum Biotechnologies
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 31 Jul 2025 BGTF 027 is still in preclinical development for Eye disorders (Blue Gen Therapeutics pipeline, July 2025)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Eye-disorders in USA (Intravitreous, Injection)
- 29 Dec 2022 BGTF 027 is still in preclinical phase for Eye disorders in USA (Intravitreous) (Adverum Biotechnologies pipeline, December 2022)